UY27682A1 - Composiciones farmacéuticas - Google Patents
Composiciones farmacéuticasInfo
- Publication number
- UY27682A1 UY27682A1 UY27682A UY27682A UY27682A1 UY 27682 A1 UY27682 A1 UY 27682A1 UY 27682 A UY27682 A UY 27682A UY 27682 A UY27682 A UY 27682A UY 27682 A1 UY27682 A1 UY 27682A1
- Authority
- UY
- Uruguay
- Prior art keywords
- soluble cellulose
- cellulose ether
- water
- pharmaceutical compositions
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición farmacéutica que comprende 4-(3,-cloro-4,- fluoroanilino) -7-metoxo- 6- (3-morfollinopropoxi) quinazolina o una sal farmacéuticamente aceptable de la misma (el Agente) y un éter de celulosa soluble en agua o éster de un éter de celulosas soluble en agua. El éter de celulosa soluble un agua o éter de un éter de celulosa soluble en agua presente en la composición inhibe la velocidad de precipitación del Agente de partir de la solución.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0204392A GB0204392D0 (en) | 2002-02-26 | 2002-02-26 | Pharmaceutical compound |
GB0212462A GB0212462D0 (en) | 2002-05-30 | 2002-05-30 | Pharmaceutical compound |
GB0213267A GB0213267D0 (en) | 2002-06-11 | 2002-06-11 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27682A1 true UY27682A1 (es) | 2003-10-31 |
Family
ID=27767732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27682A UY27682A1 (es) | 2002-02-26 | 2003-02-26 | Composiciones farmacéuticas |
Country Status (30)
Country | Link |
---|---|
US (2) | US20050163835A1 (es) |
EP (1) | EP1480679B1 (es) |
JP (1) | JP4544863B2 (es) |
KR (2) | KR101002374B1 (es) |
CN (1) | CN1326569C (es) |
AR (1) | AR038848A1 (es) |
AT (1) | ATE362771T1 (es) |
AU (1) | AU2003208444B2 (es) |
BR (1) | BRPI0307786B8 (es) |
CA (1) | CA2476587C (es) |
CO (1) | CO5601038A2 (es) |
CY (1) | CY1108026T1 (es) |
DE (1) | DE60313956T2 (es) |
DK (1) | DK1480679T3 (es) |
ES (1) | ES2286406T3 (es) |
HK (1) | HK1070585A1 (es) |
IL (2) | IL163642A0 (es) |
IS (1) | IS2462B (es) |
MX (1) | MXPA04008307A (es) |
MY (1) | MY135609A (es) |
NO (1) | NO328658B1 (es) |
NZ (1) | NZ534513A (es) |
PL (1) | PL208114B1 (es) |
PT (1) | PT1480679E (es) |
RU (1) | RU2318518C2 (es) |
SA (1) | SA03240043B1 (es) |
TW (1) | TWI271193B (es) |
UA (1) | UA76325C2 (es) |
UY (1) | UY27682A1 (es) |
WO (1) | WO2003072139A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ534871A (en) | 2002-02-26 | 2007-05-31 | Astrazeneca Ab | Novel crystalline forms of the anti-cancer compound ZD1839 |
GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
JP4205757B2 (ja) | 2004-05-06 | 2009-01-07 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 4−フェニルアミノ−キナゾリン−6−イル−アミド |
WO2007031933A2 (en) | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
EP3954715A3 (en) | 2006-10-27 | 2022-05-04 | Capsugel Belgium NV | Hydroxypropyl methyl cellulose hard capsules and process of manufacture |
AU2008258627A1 (en) * | 2007-06-06 | 2008-12-11 | Basf Se | Pharmaceutical formulation for the production of rapidly disintegrating tablets |
MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
TWI471321B (zh) * | 2009-06-08 | 2015-02-01 | Abbott Gmbh & Co Kg | Bcl-2族群抑制劑之口服醫藥劑型 |
TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
SG177309A1 (en) * | 2009-07-02 | 2012-02-28 | Wyeth Llc | 3-cyanoquinoline tablet formulations and uses thereof |
SG181916A1 (en) * | 2009-12-22 | 2012-08-30 | Abbott Lab | Abt-263 capsule |
JP4574742B1 (ja) * | 2010-04-08 | 2010-11-04 | 有限会社ミールジャパン | プロポリス組成物 |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
KR102095698B1 (ko) | 2010-10-29 | 2020-04-01 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
EP2643322B1 (en) | 2010-11-23 | 2017-08-30 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
WO2012071340A1 (en) | 2010-11-23 | 2012-05-31 | Metamagnetics Inc. | Antenna module having reduced size, high gain, and increased power efficiency |
HUE031267T2 (en) | 2010-11-23 | 2017-06-28 | Abbvie Ireland Unlimited Co | Methods of treatment using selective BCL-2 inhibitors |
CN102631347B (zh) * | 2012-05-03 | 2014-06-25 | 石药集团中奇制药技术(石家庄)有限公司 | 一种吉非替尼药物组合物及其制备方法 |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
KR101332829B1 (ko) * | 2013-05-31 | 2013-11-27 | 재단법인 통합의료진흥원 | 보중익기탕을 포함하는 폐암 치료용 조성물 |
GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
KR101721831B1 (ko) * | 2014-11-06 | 2017-03-31 | 주식회사 종근당 | 로베글리타존을 함유하는 경구 투여용 약제학적 조성물 |
EP3233064A1 (en) | 2014-12-19 | 2017-10-25 | Synthon BV | Pharmaceutical composition comprising gefifinib |
FI3263110T3 (fi) * | 2015-02-26 | 2023-07-25 | Takeda Pharmaceuticals Co | Tabletti, joka käsittää metoksiureajohdannaista ja mannitolipartikkeleita |
KR101739731B1 (ko) * | 2015-12-31 | 2017-05-25 | 환인제약 주식회사 | 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물 |
CN108096251B (zh) * | 2016-11-24 | 2021-11-16 | 江苏恒瑞医药股份有限公司 | 一种吉非替尼药物组合物及其制备方法 |
CN107007562B (zh) * | 2017-02-16 | 2020-10-27 | 南京优科制药有限公司 | 一种吉非替尼片剂及其制备方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3608063A (en) * | 1969-08-15 | 1971-09-21 | Gilbert S Banker | Molecular drug entrapment process and compositions |
US4178376A (en) * | 1977-01-21 | 1979-12-11 | Interx Research Corporation | Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials |
US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
GB9207988D0 (en) * | 1992-04-10 | 1992-05-27 | Smithkline Beecham Plc | Topical composition |
JPH09501947A (ja) * | 1993-08-30 | 1997-02-25 | ワーナー−ランバート・コンパニー | 改良された錠剤コーティング方法 |
US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB2306885B (en) * | 1995-11-08 | 1999-07-14 | Reckitt & Colmann Prod Ltd | Supersaturated Pharmaceutical Compositions |
JP4713698B2 (ja) * | 1997-03-05 | 2011-06-29 | スージェン, インク. | 疎水性薬剤の処方 |
ES2287971T3 (es) * | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
WO2001034119A2 (en) * | 1999-11-12 | 2001-05-17 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
KR100397792B1 (ko) * | 2001-06-28 | 2003-09-13 | 한국과학기술연구원 | 4-(페닐아미노)-[1,4]디옥사노[2,3-g]퀴나졸린 유도체 및그의 제조방법 |
NZ534871A (en) * | 2002-02-26 | 2007-05-31 | Astrazeneca Ab | Novel crystalline forms of the anti-cancer compound ZD1839 |
KR20050104152A (ko) | 2004-04-28 | 2005-11-02 | 최승호 | 경구용 약물의 흡수를 증진하는 약제학적 조성물 |
-
2003
- 2003-02-24 UA UA20040907788A patent/UA76325C2/uk unknown
- 2003-02-24 US US10/505,231 patent/US20050163835A1/en not_active Abandoned
- 2003-02-24 MY MYPI20030631A patent/MY135609A/en unknown
- 2003-02-24 JP JP2003570883A patent/JP4544863B2/ja not_active Expired - Lifetime
- 2003-02-24 KR KR1020047013177A patent/KR101002374B1/ko active IP Right Grant
- 2003-02-24 MX MXPA04008307A patent/MXPA04008307A/es active IP Right Grant
- 2003-02-24 BR BRPI0307786A patent/BRPI0307786B8/pt not_active IP Right Cessation
- 2003-02-24 IL IL16364203A patent/IL163642A0/xx active IP Right Grant
- 2003-02-24 KR KR1020107016079A patent/KR20100090726A/ko not_active Application Discontinuation
- 2003-02-24 CN CNB038046164A patent/CN1326569C/zh not_active Expired - Lifetime
- 2003-02-24 WO PCT/GB2003/000803 patent/WO2003072139A1/en active IP Right Grant
- 2003-02-24 NZ NZ534513A patent/NZ534513A/en not_active IP Right Cessation
- 2003-02-24 PL PL372215A patent/PL208114B1/pl unknown
- 2003-02-24 AU AU2003208444A patent/AU2003208444B2/en not_active Expired
- 2003-02-24 PT PT03706732T patent/PT1480679E/pt unknown
- 2003-02-24 CA CA2476587A patent/CA2476587C/en not_active Expired - Fee Related
- 2003-02-24 RU RU2004129280/15A patent/RU2318518C2/ru active
- 2003-02-24 ES ES03706732T patent/ES2286406T3/es not_active Expired - Lifetime
- 2003-02-24 AT AT03706732T patent/ATE362771T1/de active
- 2003-02-24 EP EP03706732A patent/EP1480679B1/en not_active Expired - Lifetime
- 2003-02-24 DE DE60313956T patent/DE60313956T2/de not_active Expired - Lifetime
- 2003-02-24 DK DK03706732T patent/DK1480679T3/da active
- 2003-02-25 TW TW092103905A patent/TWI271193B/zh not_active IP Right Cessation
- 2003-02-26 AR ARP030100636A patent/AR038848A1/es not_active Application Discontinuation
- 2003-02-26 UY UY27682A patent/UY27682A1/es not_active Application Discontinuation
- 2003-03-16 SA SA03240043A patent/SA03240043B1/ar unknown
-
2004
- 2004-08-19 IL IL163642A patent/IL163642A/en unknown
- 2004-08-24 IS IS7420A patent/IS2462B/is unknown
- 2004-08-24 CO CO04082661A patent/CO5601038A2/es not_active Application Discontinuation
- 2004-09-15 NO NO20043866A patent/NO328658B1/no not_active IP Right Cessation
-
2005
- 2005-04-20 HK HK05103383A patent/HK1070585A1/xx not_active IP Right Cessation
-
2007
- 2007-07-20 CY CY20071100974T patent/CY1108026T1/el unknown
-
2008
- 2008-09-19 US US12/234,321 patent/US20090186890A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27682A1 (es) | Composiciones farmacéuticas | |
AR045161A1 (es) | Derivados de quinazolina | |
JP2005532372A5 (es) | ||
AR035482A1 (es) | Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos | |
TW200518753A (en) | Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents | |
MA27265A1 (fr) | Formulations d'agoniste opioide a antagoniste liberable et sequestre | |
GEP20053595B (en) | Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment | |
TNSN06032A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
EA200300081A1 (ru) | Гидрогель-управляемая лекарственная форма | |
RS52577B (en) | ONE-DAY OXYCODON FORMULATIONS | |
BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
ES2721899T3 (es) | Composiciones farmacéuticas que comprenden fentanilo para su administración intranasal | |
ATE415410T1 (de) | Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten | |
NZ510887A (en) | Formulations of fexofenadine for ocular and nasal delivery | |
AR034343A1 (es) | Combinaciones farmaceuticas | |
BR0007294A (pt) | Formulações farmacêuticas aperfeiçoadas | |
WO2005011647A3 (en) | Pharmaceutical composition | |
FR2850023B1 (fr) | Medicaments pour le systeme nerveux | |
AR044861A1 (es) | Una composicion para pelicula consumible via oral para suministrar agentes antiplaca y refrescantes del aliento | |
EA200300110A1 (ru) | Композиция элетриптана в виде частиц | |
ATE311928T1 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
BR0307320A (pt) | Sistema de liberação osmótico | |
ATE401900T1 (de) | Verwendung von polyethylenglycol ( peg ) zur herstellung eines medikamentes zur behandlung von verstopfung | |
AR032614A1 (es) | Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina | |
ATE363909T1 (de) | Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20160812 |